BioXcel Therapeutics (BTAI) Share-based Compensation (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Share-based Compensation of $2.8 million for Q4 2025, up 1481.91% year-over-year from $173840.5 in Q4 2024, and up 373.32% quarter-over-quarter from $581000.0 in Q3 2025.
BioXcel Therapeutics (BTAI) Share-based Compensation (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.8 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 1481.91% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $4.9 million (up 68.34% YoY), while the FY2025 annual figure was $2.8 million, down 64.02% from the prior year.
- Share-based Compensation for Q4 2025 stood at $2.8 million, up from $581000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $18.6 million in Q4 2023, with the low at -$199000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $3.6 million (2022), against an average of $3.7 million.
- Peak annual rise in Share-based Compensation reached 12614.81% in 2024, while the deepest fall reached 101.07% in 2024.
- BioXcel Therapeutics' Share-based Compensation stood at $2.2 million in 2021, then jumped by 103.35% to $4.5 million in 2022, then surged by 308.78% to $18.6 million in 2023, then tumbled by 101.07% to -$199000.0 in 2024, then soared by 1481.91% to $2.8 million in 2025.
- Business Quant data shows BTAI's Share-based Compensation at $2.8 million in Q4 2025, $581000.0 in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.42 Mn | 24.42 Mn | 160,000.00 | 358,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358,000.00 |
| Jun 30, 2026 | 358,000.00 |
| Mar 31, 2026 | 435,000.00 |
| Mar 31, 2026 | 435,000.00 |
| Dec 31, 2025 | 2.75 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Sep 30, 2025 | 581,000.00 |
| Sep 30, 2025 | 581,000.00 |
| Jun 30, 2025 | 1.56 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 180,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Dec 31, 2024 | -199,000.00 |
| Dec 31, 2024 | -199,000.00 |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Mar 31, 2024 | 3.43 Mn |